

DAFTAR PUSTAKA

1. Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part i—initial work-up and medical management. *Journal of Urology*. 2021 Oct 1;206(4):806–17.
2. Partin AW, Dmochowski RR, Kavoussi LR, Peters CA. The prostate. In: *Campbell walsh wein urology*. 12th ed. Elsevier; 2020. p. 3305–481.
3. Cornu JN, Gacci M, Hashim H, Herrmann TRW, Malde S, Netsch C, et al. EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (luts), incl. benign prostatic obstruction (BPO). Arnhem: EAU Guidelines Office; 2023. p. 6–34.
4. Tortora GJ, Derrickson B. The reproductive systems. In: *Principles of anatomy and physiology*. 15th ed. New York: Wiley; 2017. p. 1066.
5. Awedew AF, Han H, Abbasi B, Abbasi KM, Ahmed MB, Almidani O, et al. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the global burden of disease study 2019. *Lancet Healthy Longev*. 2022 Nov;3(11):754–76.
6. Putri AE. *Statistik JKN 2015-2019 fakta dan data capaian program jaminan kesehatan nasional*. 1st ed. Jakarta: Dewan Jaminan Sosial Nasional; 2021. p. 91–3.
7. Ishak M, MYH E, Yunir PE. Hubungan intravesical prostatic protrusion (IPP) terhadap perubahan international prostate symptoms score (IPSS) pada pasien benign prostatic hyperplasia (BPH) yang diterapi dengan α -blocker di Kota Padang. *Jurnal Ilmu Bedah Indonesia*. 2021 Jul 28;49(1):25–39.
8. Madersbacher S, Sampson N, Culig Z. Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: a mini-review. *Gerontology*. 2019 Aug 1;65(5):458–64.
9. Rastrelli G, Vignozzi L, Corona G, Maggi M. Testosterone and benign prostatic hyperplasia. *Sex Med Rev*. 2019 Apr;7(2):259–71.
10. Purnomo BB. Hiperplasia prostat benigna. In: *Dasar-dasar urologi*. 3rd ed. Malang: Sagung Seto; 2016. p. 125–44.
11. Rodríguez JZ, O’Kennedy R. New approaches for the development of diagnostic systems for prostate cancer. *Asian Hospital & Health Care Management*. 2017;18–23.

12. Sjamsuhidajat R. Pemeriksaan penderita. In: Sjamsuhidajat R, Karnadihardja W, Prasetyono TOH, Rudiman R, editors. Buku ajar ilmu bedah Sjamsuhidajat-de Jong. 3rd ed. Jakarta: EGC; 2012. p. 293–4.
13. Romero FR, Romero AW, Filho TB, Kulysz D, Oliveira FC, Filho RT. The prostate exam. *Health Educ J.* 2012 Mar 20;71(2):239–50.
14. Udeh E, Dakum N, Aderibigbe S, Edeh J. The utility of digital rectal examination in estimating prostate volume in a rural hospital setting. *Nigerian Journal of Surgery.* 2015;21(2):111.
15. Lodh B, Sinam R, Singh K. Digital rectal grading of benign prostatic hyperplasia: where does it stand today?. *Journal of Mahatma Gandhi Institute of Medical Sciences.* 2016;21(1):40.
16. Su MZ, Lenaghan D, Woo HH. Dichotomous estimation of prostate volume: a diagnostic study of the accuracy of the digital rectal examination. *World J Mens Health.* 2013;31(3):220.
17. David MK, Leslie SW. Prostate specific antigen. *StatPearls* [Internet]. 2022 Nov 10 [cited 2024 Jan 27]; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK557495/>
18. Scarpato KR, Albertsen PC. Prostate-specific antigen screening guidelines. In: *Prostate cancer.* Elsevier; 2016. p. 111–6.
19. Bohnen AM, Groeneveld FP, Bosch JLHR. Serum prostate-specific antigen as a predictor of prostate volume in the community: the krimpens study. *Eur Urol.* 2007 Jun;51(6):1645–53.
20. Brunnicardi FC, Andersen D, Billiar T, Dunn D, Hunter J, Kao L, et al. *Schwartz's principles of surgery.* 11th ed. Mc Graw Hill Medical; 2019. p. 1760.
21. Mescher AL. The male reproductive system. In: *Junqueira's basic histology: Text and Atlas.* 15th ed. Mc Graw Hill Medical; 2018. p. 453–5.
22. Graham SD, Keane TE. Prostate. In: *Glenn's urologic surgery .* 8th ed. Wolters Kluwer Health; 2015. p. 606–10.
23. Wineski LE. Pelvis, part II : pelvic cavity. In: *Snell's clinical anatomy by regions.* 10th ed. Walters Kluwer; 2018. p. 453–5.
24. Smith J, Howards S, Preminger G, Dmochowski R. Prostate: malignancy. In: *Hinman's atlas of urologic surgery.* 4th ed. Elsevier; 2019. p. 540.
25. Purnomo BB. Anatomi sistem urogenitalia. In: *Dasar-dasar urologi.* 3rd ed. Malang : Sagung Seto; 2016. p. 16.

26. Kumar V, Abbas AK, Aster JC. Male genital system and lower urinary tract. In: Robbins basic pathology. 10th ed. Philadelphia: Elsevier; 2017. p. 697–8.
27. Partin AW, Dmochowski RR, Kavoussi LR, Peters CA. Reproductive and sexual function. In: Campbell walsh wein urology. 12th ed. Elsevier; 2020. p. 1378–9.
28. Eroschenko VP. Male reproductive system. In: diFiore's atlas of histology with functional correlations. 12th ed. Philadelphia: Lippincott Williams & Wilkins; 2013. p. 496–7.
29. Hall JE, Hall ME. Reproductive and hormonal functions of the male (and function of the pineal gland). In: Guyton and hall textbook of medical physiology. 14th ed. Philadelphia: Elsevier; 2020. p. 1014.
30. Sherwood L. The reproductive system. In: Human physiology: from cells to systems. 9th ed. Boston: Cengage Learning; 2016. p. 731.
31. Institute for Quality and Efficiency in Health Care. How does the prostate work?. 2016 Aug 23 [cited 2024 Jan 29]; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK279291/>
32. Sjamsuhidajat R. Saluran kemih dan alat kelamin lelaki. In: Sjamsuhidajat R, Karnadihardja W, Prasetyono TOH, Rudiman R, editors. Buku ajar ilmu bedah Sjamsuhidajat-de Jong. 3rd ed. Jakarta: EGC; 2012. p. 899.
33. Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms. *Urologic Clinics of North America*. 2016 Aug;43(3):289–97.
34. Umam IAC, Irawiraman H, Sawitri E. Hubungan usia dengan kadar prostate specific antigen pada penderita benign prostatic hyperplasia di laboratorium patologi anatomi RSUD Abdul Wahab Sjahranie Samarinda. *Jurnal Sains dan Kesehatan*. 2020 Dec 31;2(4):467–71.
35. Prasetyo ZA, Budaya TN, Daryanto B. Characteristics of benign prostatic hyperplasia (BPH) patients undergoing transurethral resection of the prostate (TURP). *Jurnal Kedokteran Brawijaya*. 2021 Aug 31;31(4):220–3.
36. Hammes SR, Levin ER. Impact of estrogens in males and androgens in females. *J Clin Invest*. 2019 May 1;129(5):1818–26.
37. Araujo AB, Wittert GA. Endocrinology of the aging male. *Best Pract Res Clin Endocrinol Metab*. 2011 Apr;25(2):303–19.
38. Nicholson TM, Rieke WA. Androgens and estrogens in benign prostatic hyperplasia: past, present and future. *Differentiation*. 2011 Nov;82(4–5):184–99.

39. Banerjee PP, Banerjee S, Brown TR, Zirkin BR. Androgen action in prostate function and disease. *Am J Clin Exp Urol*. 2018;6(2):62–77.
40. Tong Y, Zhou R yuan. Review of the roles and interaction of androgen and inflammation in benign prostatic hyperplasia. *Mediators Inflamm*. 2020 Oct 28;2020:1–7.
41. Ng M, Baradhi KM. Benign prostatic hyperplasia. *StatPearls* [Internet]. 2022 Aug 8 [cited 2023 Oct 7]; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK558920/>
42. Gangavarapu KJ, Jowdy PF, Foster BA, Huss WJ. Role of prostate stem cells and treatment strategies in benign prostate hyperplasia. *Am J Clin Exp Urol*. 2022;10(3):154–69.
43. Brennen WN, Isaacs JT. Mesenchymal stem cells and the embryonic reawakening theory of BPH. *Nat Rev Urol*. 2018 Nov 13;15(11):703–15.
44. Patel N, Parsons JK. Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. *Indian Journal of Urology*. 2014;30(2):170.
45. Michaud JE, Billups KL, Partin AW. Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk. *Ther Adv Urol*. 2015 Dec 6;7(6):378–87.
46. Cannarella R, Condorelli RA, Barbagallo F, LaVignera S, Calogero AE. Endocrinology of the aging prostate: current concepts. *Front Endocrinol (Lausanne)*. 2021 Feb 22;12.
47. Platz EA, Joshu CE, Mondul AM, Peskoe SB, Willett WC, Giovannucci E. Incidence and progression of lower urinary tract symptoms in a large prospective cohort of united states men. *Journal of Urology*. 2012 Aug;188(2):496–501.
48. Kementerian Kesehatan. Kelompok usia. 2023.
49. Alamsyah LL, Alvarino, Rahmatini, Etriyel, Miro S. Korelasi antara durasi operasi dengan penurunan kadar hemoglobin pada pasien benign prostate hyperplasia (BPH) yang ditatalaksana transurethral resection of prostate (TURP). 2023.
50. Xia SJ, Cui D, Jiang Q. An overview of prostate diseases and their characteristics specific to Asian men. *Asian J Androl*. 2012 May;14(3):458.
51. Chen Z, Miao L, Gao X, Wang G, Xu Y. Effect of obesity and hyperglycemia on benign prostatic hyperplasia in elderly patients with newly diagnosed type 2 diabetes. *Int J Clin Exp Med*. 2015 Jul 30;8(7):11289.

52. Ajayi A, Abraham K. Understanding the role of estrogen in the development of benign prostatic hyperplasia. *African Journal of Urology*. 2018 Jun;24(2):93–7.
53. Habib CN, Al-Abd AM, Tolba MF, Khalifa AE, Khedr A, Mosli HA, et al. Leptin influences estrogen metabolism and accelerates prostate cell proliferation. *Life Sci*. 2015 Jan;121:10–5.
54. Kopp W. Diet-induced hyperinsulinemia as a key factor in the etiology of both benign prostatic hyperplasia and essential hypertension?. *Nutr Metab Insights*. 2018 May 6;11.
55. Fibbi B, Penna G, Morelli A, Adorini L, Maggi M. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. *Int J Androl*. 2010 Jun 3;33(3):475–88.
56. Chughtai B, Lee R, Te A, Kaplan S. Role of inflammation in benign prostatic hyperplasia. *Rev Urol*. 2011;13(3):147–50.
57. Wolin KY, Grubb RL, Pakpahan R, Ragard L, Mabie J, Andriole GL, et al. Physical activity and benign prostatic hyperplasia-related outcomes and nocturia. *Med Sci Sports Exerc*. 2015 Mar 26;47(3):581.
58. Kim DY, Chung TH, Kim SJ, Kim JH, Hwang HA. Association between benign prostate hyperplasia and occupational group. *Korean Journal of Family Practice*. 2019 Apr 20;9(2):196–203.
59. Foo KT. Pathophysiology of clinical benign prostatic hyperplasia. *Asian J Urol*. 2017 Jul 1;4(3):152.
60. Babinski MA, Manaia JHM, Cardoso GP, Costa WS, Sampaio FJ. Significant decrease of extracellular matrix in prostatic urethra of patients with benign prostatic hyperplasia. *Histol Histopathol*. 2014 Jan;29(1):57–63.
61. Das K, Buchholz N. Benign prostate hyperplasia and nutrition. *Clin Nutr ESPEN*. 2019 Oct;33:5–11.
62. Vasanwala FF, Wong MYC, Ho HSS, Foo KT. Benign prostatic hyperplasia and male lower urinary symptoms: a guide for family physicians. *Asian J Urol*. 2017 Jul;4(3):181–4.
63. Purnomo BB. Pemeriksaan urologi. In: *Dasar-dasar urologi*. 3rd ed. Malang: Sagung Seto; 2016. p. 24–6.
64. Tjahjodjati, Soebadi DM, Umbas R, Mochtar CA, Daryanto B, Noegroho BS, et al. *Panduan penatalaksanaan klinis pembesaran prostat jinak (benign prostatic hyperplasia/BPH)*. 4th ed. Ikatan Ahli Urologi Indonesia (IAUI); 2021.

65. Monoarfa RA, Mochtar CA. Validation of Indonesian version of IPSS. *Indonesian Journal of Urology*. 2014 Jan 2;21(1).
66. Putra IBOW, Hamid ARAH, Rasyid N, Mochtar CA, Umbas R. Comparison of visual prostate symptom score with the international prostate symptom score and uroflowmetry parameters in assessing men with lower urinary tract symptoms in Dr. Cipto Mangunkusumo National General Hospital, Indonesia. *Prostate Int*. 2019 Sep;7(3):91–5.
67. Tjahjodjati, Soebadi DM, Umbas R, Purnomo BB, Widjanarko S, Mochtar CA, et al. *Panduan penatalaksanaan klinis pembesaran prostat jinak (benign prostatic hyperplasia/BPH)*. 3rd ed. Ikatan Ahli Urologi Indonesia (IAUI); 2017.
68. Kim EH, Larson JA, Andriole GL. Management of benign prostatic hyperplasia. *Annu Rev Med*. 2016 Jan 14;67(1):137–51.
69. Reis LO, Simao AFL, Baracat J, Denardi F, Gugliotta A. Digital rectal examination standardization for inexperienced hands: teaching medical students. *Adv Urol*. 2013;2013:1–5.
70. Skinder D, Zacharia I, Studin J, Covino J. Benign prostatic hyperplasia. *JAAPA*. 2016 Aug;29(8):19–23.
71. Netto GJ, Epstein JI. Immunohistology of the prostate, bladder, kidney, and testis. In: *Diagnostic immunohistochemistry*. Elsevier; 2011. p. 593–661.
72. Dasgupta A, Wahed A. Tumor markers. In: *Clinical chemistry, immunology and laboratory quality control*. Elsevier; 2014. p. 229–47.
73. Barrett KE, Barman SM, Brooks HL, Yuan J. Endocrine & reproductive physiology. In: *Ganong's review of medical physiology*. 26th ed. 2019. p. 416.
74. Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. *Journal of Clinical Oncology*. 2003 Jan 15;21(2):383–91.
75. Sandhu JS, Bixler BR, Dahm P, Goueli R, Kirkby E, Stoffel JT, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline amendment 2023. *Journal of Urology*. 2023 Sep 14.
76. Ene C, Geavlete P, Geavlete B. What's new in bipolar TURP for surgical management of BPH?. *Chirurgia (Bucur)*. 2020;115(3):307.
77. Alexander CE, Scullion MMF, Omar MI, Yuan Y, Mamoulakis C, N'Dow JMO, et al. Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction. *Cochrane Database Syst Rev*. 2019 Dec 3;2019(12).

78. Kim SJ, Al-Hussein AO, Chughtai B, Lee RK. Lower urinary tract symptoms following transurethral resection of prostate. *Curr Urol Rep.* 2018 Oct 20;19(10):85.
79. Haibin W, Lin Q, Junxiu W, Heng W, Qi Z, Yanpeng W, et al. Transurethral laser versus open simple prostatectomy for large volume prostates: a systematic review and meta-analysis of randomized controlled trials. *Lasers Med Sci.* 2021 Aug 12;36(6):1191–200.
80. Smith J, Howard S, Preminger G, Dmochowski R. Prostate: benign. In: *Hinman's atlas of urologic surgery.* 4th ed. Elsevier; 2019. p. 491–520.
81. Dahlan MS. Besar sampel dalam penelitian kedokteran dan kesehatan. 3rd ed. 2010. p. 38–41.
82. Ulfangingtyas K, Norahmawati E, Anita KW, Angelina A, Seputra KP. Profil klinikopatologi adenokarsinoma prostat di RSUD Dr. Saiful Anwar Malang periode tahun 2015 - 2019: sebuah penelitian retrospektif. *Majalah Kesehatan.* 2021 Jun 30;8(2):87–99.
83. Sastroasmoro S, Ismael S. *Dasar-dasar metodologi penelitian klinis.* 5th ed. 2014. p. 381.
84. Kementerian Kesehatan. Tabel batas ambang indeks massa tubuh (IMT). 2019.
85. Nadilla S, Sangadji A, Ariwicaksono SC. Karakteristik pasien benign prostatic hyperplasia (BPH) berdasarkan transabdominal ultrasonography (TAUS) di RSUD Al-Fatah Ambon periode 2019-2021. *Jurnal Kesehatan Tambusai.* 2023 Oct 23;4(4):4648–57.
86. Prasetyo IL, Musthofa FL, Purnanto E. Hubungan antara volume spesimen TUR prostat dengan usia di Rumah Sakit Pertamina Bintang Amin Bandar Lampung tahun 2020 dan 2021. *Medical Profession Journal of Lampung.* 2022 Jun 20;12(1):26–30.
87. Shao WH, Zheng CF, Ge YC, Chen XR, Zhang BW, Wang GL, et al. Age-related changes for the predictors of benign prostatic hyperplasia in Chinese men aged 40 years or older. *Asian J Androl.* 2023;25(1):132.
88. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the massachusetts male aging study. *J Clin Endocrinol Metab.* 2002 Feb;87(2):589–98.
89. Alfiansyah D, Permatasari TAE, Jumaiyah W, Azzam R, Kurniasih DN. Faktor-faktor yang mempengaruhi kejadian benign prostatic hyperplasia di unit rawat jalan. *Jurnal Keperawatan.* 2022;14.

90. Badan Pusat Statistik. Angka harapan hidup (AHH) menurut jenis kelamin dan kabupaten/kota (tahun), 2020-2022. 2022.
91. Badan Pusat Statistik. Angka harapan hidup (AHH) menurut provinsi dan jenis kelamin (tahun), 2022-2023. 2024.
92. Nurmariana, Virgiandhy I, Fitriangga A. Gambaran karakteristik dan tingkat keparahan obstruksi pasien benign prostatic hyperplasia (BPH) di RSUD Dr. Soedarso Pontianak tahun 2013. *Jurnal Mahasiswa Fakultas Kedokteran Untan*. 2015.
93. Prathiwinda GG. Hubungan indeks massa tubuh dengan kadar prostate specific antigen dan nilai international prostate symptom score pada pasien benign prostatic hyperplasia di RSUP Denpasar. 2015.
94. Soenen S, Rayner CK, Jones KL, Horowitz M. The ageing gastrointestinal tract. *Curr Opin Clin Nutr Metab Care*. 2016 Jan;19(1):12–8.
95. Loeb S, Kettermann A, Carter HB, Ferrucci L, Metter EJ, Walsh PC. Prostate volume changes over time: results from the Baltimore longitudinal study of aging. *Journal of Urology*. 2009 Oct;182(4):1458–62.
96. Pejic T, Acimovic M, Dzamic Z, Radovanovic M, Hadzi DJ. Benign prostatic hyperplasia and prostate-specific antigen. *Vojnosanit Pregl*. 2015;72(5):447–53.
97. Zhang SJ, Qian HN, Zhao Y, Sun K, Wang HQ, Liang GQ, et al. Relationship between age and prostate size. *Asian J Androl*. 2013 Jan 10;15(1):116–20.
98. Wulansari NS, Marindawati M. Profil prostate spesifik antigen (PSA) pada penyakit prostat di Rumah Sakit Umum Daerah Cengkareng Jakarta Barat. *Muhammadiyah Journal of Geriatric*. 2020 Apr 4;1(1):18.
99. Van S, Heyns C, Zarrabi A. Comparison of men with acute versus chronic urinary retention: aetiology, clinical features and complications. *African Journal Online*. 2011;53(6):590–4.
100. Djatisoesanto W, Soebadi DM, Sudiana IK. Urinary retention effect in the increased of expression within prostatic tissue. *Indonesian Journal of Urology*. 2015 Oct 1;22(2).
101. Cormio L, Lucarelli G, Selvaggio O, DiFino G, Mancini V, Massenio P, et al. Absence of Bladder Outlet Obstruction Is an Independent Risk Factor for Prostate Cancer in Men Undergoing Prostate Biopsy. *Medicine*. 2016 Feb;95(7):e2551.
102. Putra IBOW, Hamid ARAH, Mochtar CA, Umbas R. Relationship of age, prostate-specific antigen, and prostate volume in Indonesian men with benign prostatic hyperplasia. *Prostate Int*. 2016 Jun;4(2):43–8.

103. Alawad A, Younis F, Eltoun AM, Abdelgani SA. Serum prostate-specific antigen as a predictor of prostate volume in Sudanese patients with benign prostatic hyperplasia. *Int J Med (Dubai)*. 2014 May 20;2(1):40.
104. Duarsa GWK, Sari YA, Oka AAG, Santosa KB, Yudiana IW, Tirtayasa PMW, et al. Serum testosterone and prostate-specific antigen levels are major risk factors for prostatic volume increase among benign prostatic hyperplasia patients. *Asian J Urol*. 2021 Jul;8(3):289–97.
105. Yustina M, Duarsa GWK, Oka AAG, Yudiana IW, Santosa IKB, Mahadewa TGB. Hubungan prostate specific antigen (PSA) dengan rasio stromal epitelial prostat pada pasien pembesaran prostat jinak. *Medicina (B Aires)*. 2019 Aug 1;50(2).

